DrugPatentWatch Database Preview
Abbvie Inc Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for ABBVIE INC, and when can generic versions of ABBVIE INC drugs launch?
ABBVIE INC has ten approved drugs.
There are fifty-one US patents protecting ABBVIE INC drugs.
There are one thousand and ten patent family members on ABBVIE INC drugs in fifty-three countries and ninety-eight supplementary protection certificates in nineteen countries.
Summary for Abbvie Inc
| International Patents: | 1010 |
| US Patents: | 51 |
| Tradenames: | 10 |
| Ingredients: | 9 |
| NDAs: | 10 |
| Drug Master File Entries: | 15 |
| Patent Litigation for Abbvie Inc: | See patent lawsuits for Abbvie Inc |
Drugs and US Patents for Abbvie Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | DISCN | Yes | No | 7,148,359*PED | Start Trial | Start Trial | ||||
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | DISCN | Yes | No | 9,006,387 | Start Trial | Start Trial | ||||
| Abbvie Inc | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-003 | Apr 11, 2016 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Abbvie Inc | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-001 | Apr 11, 2016 | RX | Yes | No | Start Trial | Start Trial | |||||
| Abbvie Inc | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | DISCN | Yes | No | 8,492,386 | Start Trial | Start Trial | ||||
| Abbvie Inc | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-002 | Apr 11, 2016 | RX | Yes | No | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Abbvie Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | 6,037,157*PED | Start Trial |
| Abbvie Inc | TRICOR | fenofibrate | TABLET;ORAL | 021203-001 | Sep 4, 2001 | 6,277,405 | Start Trial |
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | 6,703,403*PED | Start Trial |
| Abbvie Inc | TRICOR | fenofibrate | TABLET;ORAL | 021203-003 | Sep 4, 2001 | 4,895,726 | Start Trial |
| Abbvie Inc | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | 7,148,359 | Start Trial |
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | 7,148,359*PED | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ABBVIE INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 145 mg | ➤ Subscribe | 2007-10-19 |
| ➤ Subscribe | Tablets | 100 mg | ➤ Subscribe | 2010-12-21 |
| ➤ Subscribe | Tablets | 48 mg | ➤ Subscribe | 2008-07-01 |
| ➤ Subscribe | Capsules | 100 mg | ➤ Subscribe | 2012-10-31 |
International Patents for Abbvie Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2968301 | Start Trial |
| Uruguay | 31881 | Start Trial |
| Hungary | E034804 | Start Trial |
| China | 108368121 | Start Trial |
| Taiwan | I600656 | Start Trial |
| South Africa | 201200950 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Abbvie Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2340029 | C 2015 019 | Romania | Start Trial | PRODUCT NAME: PARITAPREVIR; NATIONAL AUTHORISATION NUMBER: EU/1/14/982; DATE OF NATIONAL AUTHORISATION: 20150115; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/982; DATE OF FIRST AUTHORISATION IN EEA: 20150115 |
| 2618831 | 300 50016-2017 | Slovakia | Start Trial | PRODUCT NAME: GLECAPREVIR VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/17/1213 20170728 |
| 2435432 | C20170017 00231 | Estonia | Start Trial | PRODUCT NAME: VENETOKLAKS;REG NO/DATE: EU/1/16/1138 07.12.2016 |
| 2340029 | 1590012-9 | Sweden | Start Trial | PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REG. NO/DATE: EU/1/14/982 20150119 |
| 2435432 | C02435432/01 | Switzerland | Start Trial | PRODUCT NAME: VENETOCLAX; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66235 08.05.2018 |
| 2340029 | PA2015011 | Lithuania | Start Trial | PRODUCT NAME: PARITAPREVIRUM; REGISTRATION NO/DATE: EU/1/14.982 20150115 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
